BioCentury
ARTICLE | Financial News

Protein misfolding company Orphazyme adds €14M to series B

March 10, 2017 9:46 PM UTC

Orphazyme ApS (Copenhagen, Denmark) added €14 million ($14.9 million) in the second and final close of its series B round, bringing the round's total to €34 million. New investors LSP and the ALS Investment Fund participated, as did existing investors Kurma Partners, Idinvest Partners, Novo A/S (Hellerup, Denmark), Sunstone Capital and Aescap Venture.

The protein misfolding company announced the round's €20 million first close in January 2015...

BCIQ Company Profiles

Orphazyme A/S

BCIQ Target Profiles

Heat shock protein 70 (Hsp70)